Efficacy, Safety, and Biomarker Analysis of Toripalimab Monoclonal Antibody Combined with Gemcitabine and Cisplatin Chemotherapy as Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial | Synapse
February 20, 2026
Efficacy, Safety, and Biomarker Analysis of Toripalimab Monoclonal Antibody Combined with Gemcitabine and Cisplatin Chemotherapy as Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial
Key Points
The aim is to evaluate the efficacy and safety of Toripalimab combined with chemotherapy for treating muscle-invasive bladder cancer.
Phase II clinical trial design
Combination of Toripalimab with gemcitabine and cisplatin
Assessment of treatment efficacy and safety
Biomarker analysis during treatment
Demonstrated good efficacy of the treatment combination
Showed a favorable safety profile
Suggests Toripalimab as a promising candidate for neoadjuvant therapy in muscle-invasive bladder cancer
Abstract
Toripalimab combined with GC chemotherapy demonstrates a good efficacy and safety, making it a promising therapeutic strategy for NAT of MIBC.